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The binding affinity of PTPN13’s tandem
PDZ2/3 domain is allosterically modulated
Markus Dicks1, Gerd Kock1, Bastian Kohl1, Xueyin Zhong1, Stefanie Pütz1, Rolf Heumann2, Kai S. Erdmann3 and
Raphael Stoll1*
Abstract
Background: Protein tyrosine phosphatase PTPN13, also known as PTP-BL in mice, is a large multi-domain non-
transmembrane scaffolding protein with a molecular mass of 270 kDa. It is involved in the regulation of several
cellular processes such as cytokinesis and actin-cytoskeletal rearrangement. The modular structure of PTPN13
consists of an N-terminal KIND domain, a FERM domain, and five PDZ domains, followed by a C-terminal protein
tyrosine phosphatase domain. PDZ domains are among the most abundant protein modules and they play a
crucial role in signal transduction of protein networks.
Results: Here, we have analysed the binding characteristics of the isolated PDZ domains 2 and 3 from PTPN13 and
compared them to the tandem domain PDZ2/3, which interacts with 12 C-terminal residues of the tumour suppressor
protein of APC, using heteronuclear multidimensional NMR spectroscopy. Furthermore, we could show for the first
time that PRK2 is a weak binding partner of PDZ2 and we demonstrate that the presence of PDZ3 alters the binding
affinity of PDZ2 for APC, suggesting an allosteric effect and thereby modulating the binding characteristics of PDZ2. A
HADDOCK-based molecular model of the PDZ2/3 tandem domain from PTPN13 supports these results.
Conclusions: Our study of tandem PDZ2/3 in complex with APC suggests that the interaction of PDZ3 with PDZ2
induces an allosteric modulation within PDZ2 emanating from the back of the domain to the ligand binding site. Thus,
the modified binding preference of PDZ2 for APC could be explained by an allosteric effect and provides further
evidence for the pivotal function of PDZ2 in the PDZ123 domain triplet within PTPN13.
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Background
In biological processes, signal transduction depends on
protein networks that include a vast number of highly
specialised protein domains [1, 2]. The interaction of
proteins can also be thought of as an energy distribution
over intra domain pathways and binding surfaces that
cause specific changes in the structure and function of
proteins [3–5]. One of the most important protein mod-
ules in signal transduction are PDZ domains [1, 2],
which are found ubiquitously in the eukaryotic genome.
PDZ is an acronym for PSD95, a synapse associated pro-
tein, the septate junction protein Disc-large, and the
tight junction protein Zonula occludens-1. The main
function of PDZ domains is to provide a scaffold for
membrane-associated protein complexes [2] by binding
to C-terminal fragments of receptors, ion channels, and
other integral membrane proteins. PDZ domains contain
about 90 amino acids and they share a common globular
fold that consists of two α-helices 1 and 2 (termed DA
and DB) as well as six β-strands 1 to 6 (denoted from
EA to EF), which form two anti-parallel β-sheets [6, 7].
PDZ domains bind to C-terminal peptides through a
conserved binding loop, which consists of four amino
acids that are part of binding groove formed by α-helix
DA and β-strand EB. The positions P0 and P− 2 of the
peptide ligand are crucial for binding and define differ-
ent PDZ binding classes [8–11]. This nomenclature is
based on the accommodation of the carboxy-terminal
peptide ligand residues by the canonical PDZ binding
cleft. Here, the carboxylate moiety of the last ligand
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residue, i.e. P0, is bound to GLGF motif of PDZ do-
mains, which causes ligand amino acid side chains of P0
and P
− 2 to be orientated towards the PDZ binding
pocket and side chains in position P
− 1 and P− 3 to point
away from the PDZ binding cleft into the solvent [12].
Recently, more general concepts have been introduced,
which do not (entirely) rely on specific definitions of
PDZ ligand classes [13, 14].
Tyrosine-protein phosphatase non-receptor type 13
(PTPN13), which is known as protein tyrosine phosphat-
ase PTP-Basophil/Basophil-like (PTP-BL) in mice, is the
central scaffolding component of a supramolecular pro-
tein complex that exhibits numerous domain-specific in-
teractions [1]. The PTPN13-interacting proteins can
mainly be divided into three groups: known or potential
regulators of the actin cytoskeleton, regulators of the
actin and tubulin cytoskeleton, and regulators of gene
transcription. Two of known ligand peptides of PTPN13
are derived from the tumour suppressor protein aden-
omatous polyposis coli (APC), a class I-type ligand [11,
15], and the cytosolic protein kinase C-related kinase-2
(PRK2), a class III-type ligand. The most important role
of APC is the regulation of β-catenin, which is involved
in cell adhesion processes via the transmembrane recep-
tor cadherin [16]. APC also plays a role in the regulation
of transcription through the transcription factor lympho-
cyte enhancer binding factor/T-cell factor (LEF/TCF)
[17, 18]. PRK2 is a cytosolic serine/threonine kinase that
is regulated by the monomeric G-protein Rho [19, 20].
For the tandem domain PDZ1/2 of PTPN13, also known
as PTP-BL in mice, an allosteric effect on peptide bind-
ing has already been observed [21]. PTPN13 represents
a large multi-domain non-transmembrane scaffolding
protein with different functional properties [1]. The N-
terminal part of this protein consists of a kinase non-
catalytic C-lobe domain (KIND), followed by a four
point one, Ezrin, Radixin, Moesin (FERM) domain. In
addition, PTPN13 contains five PDZ domains and a C-
terminal protein tyrosine phosphatase domain. It has
previously been reported for other PDZ-containing pro-
teins, e.g. the glutamate receptor interacting protein
(GRIP) and X11/Mint, that the binding characteristics of
single domains differ from PDZ tandem and that allo-
steric effects can indeed regulate the binding properties
of PDZ tandem domains [10, 22, 23].
Here, we describe the binding characteristics of the sec-
ond and third PDZ domain of PTPN13, both individually
and as a PDZ2/3 tandem domain through heteronuclear
multidimensional nuclear magnetic resonance (NMR)
spectroscopy. Our results reveal that PRK2 is an add-
itional binding partner of the PDZ2 domain. Furthermore,
we have discovered an allosteric effect due to an inter-
action of the PDZ3 domain with the opposite surface of
the canonical PDZ2 ligand binding site, which is
structurally broadcasted to the binding pocket of PDZ2.
The analysis of the interaction between PDZ2 and PDZ3
as well as with their respective ligands sheds light on the
pivotal role of the PDZ2 domain within the PDZ123 cas-
sette of PTPN13 on a molecular level.
Results
Peptide binding to PDZ domains of PTPN13
We have applied multidimensional heteronuclear NMR
spectroscopy in order to elucidate the binding affinities of
the PDZ2 single domain and the tandem domain PDZ2/3
of PTPN13 for the chemically synthesized C-terminal
dodecapeptides derived from APC and PRK2. The binding
characteristics were analyzed in a titration series of the
dodecamer peptides and 15N isotopically-enriched PDZ2
and PDZ2/3 samples, respectively, and by monitoring the
NMR chemical shift perturbations in a series of 2D
1H-15N heteronuclear single quantum coherence (HSQC)
spectra with increasing ligand concentrations. It could be
shown that all peptides bind to the canonical binding
groove of PDZ domains (Figs. 1, 2, 3 and 4).
Peptide binding characteristics of the PDZ2 domain
The binding study presented here revealed for the first
time that the PDZ2 domain also interacts with the PRK2
peptide. The NMR chemical shift perturbations observed
in 2D 1H-15N-HSQC spectra for the PDZ2-PRK2 complex
demonstrate that, in comparison to PDZ3 (KD = 318 ±
47 μM), the PRK2 peptide only weakly binds to the PDZ2
domain (KD = 661 ± 71 μM) (Fig. 1a, b, c) [12]. In particu-
lar, NMR chemical shift differences were observed for the
canonical ligand binding groove of PDZ2 including G23,
S24, which are also involved in peptide recognition, and
S28, and G31. Additional NMR chemical shift perturba-
tions were observed for the β-strands EA and EF of PDZ2,
located opposite to its canonical peptide binding groove.
Furthermore, we titrated an APC-derived peptide, a well-
known PDZ2 ligand [1], to PDZ2 and determined an affin-
ity of 286 ± 21 μM (Table 1). Noteworthy, chemical shift
changes cannot exclusively be attributed to structural
changes, as structural and dynamical changes as well as
direct effects of neighboring groups of the ligand all can
induce chemical perturbations. Nonetheless, it is interest-
ing to note that, upon canonical binding to PDZ2, the
APC-derived peptide leads to NMR chemical shift differ-
ences observed along intra-domain signal pathways as
previously predicted [3–5]. In concordance with former
studies [4, 5, 24], chemical differences were observed for
the binding loop and along intra-domain signaling path-
ways. Based on these results, dissociation constants KD
were extracted for the interaction of the APC-derived pep-
tide with the PDZ2 domain (Table 1).
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Peptide binding characteristics of the tandem domain
PDZ2/3
A titration of single PDZ3 to the 15N isotopically-
enriched single domain of PDZ2 only yielded minor
chemical shift differences between the respective 2D
1H-15N-HSQC NMR spectra at a molar ratio of 1:1
(Fig. 2). Interestingly, the titration results of the tandem
domain with the APC derived peptide significantly differ
from that of the binding study with the isolated domain.
The observed differences for APC binding to PDZ2 ver-
sus tandem PDZ2/3 are not large yet still considerable.
Notably, the results listed in Table 1 indicate, that APC
exhibits a slightly higher affinity to PDZ2 (KD = 211 ±
70 μM) in the PDZ2/3 tandem domain than for the
single PDZ2 domain (KD = 286 ± 21 μM), while the ex-
tracted KD value for PDZ3 (KD = 2574 ± 770 μM) is even
higher in comparison to the single PDZ3 domain (KD =
721 ± 148 μM). Binding of APC to the tandem PDZ2/3
domain occurs in the fast exchange NMR regime. At a
final stoichiometric ratio between APC and PDZ2/3 of
30:1, no further chemical shift changes were observed
for amide resonances originating from the PDZ2 do-
main. However, due to the extremely low affinity of
PDZ3 for APC, PDZ3 was not fully saturated at the end
of the titration and thus represented a fractionally APC-
bound state (data not shown). NMR chemical shift per-
turbations extracted from 2D 1H-15N-HSQC NMR spec-
tra for the PDZ2/3 titration with the APC peptide are
observed for both domains. As can be seen in Figs. 3
and 4, major chemical shift perturbations upon binding
of the APC derived peptide are however mainly re-
stricted to the PDZ2 domain. These observed chemical
shifts differences of the PDZ2 domain are located at the
canonical binding site and on the surface opposite to the
β-strands EA and EF. Figure 4 shows representative re-
gions of 2D 1H-15N-HSQC NMR spectra of the PDZ2/3
tandem domain upon titration with the APC peptide.
For example, NMR chemical shift perturbations were
observed for G12, L19, T31, G63, H94, L95, L97 of
PDZ2 and K152 as well as S231 of PDZ3 in the tandem
domain upon titration with APC (Fig. 4 a, b). All data
are consistent with fast exchange kinetics and relatively
weak (PDZ) binding affinities (Table 1).
The interaction between PDZ2 and PDZ3 alters the
binding specificity of PDZ2 in the APC-bound PDZ2/3
tandem
NMR spectroscopy was applied in order to prove as
to whether the observed differences in binding affinity
of PDZ2/3 for the APC derived peptide in contrast to
the single PDZ2 could be explained by a PDZ
domain-domain interaction. Thus, we titrated the sin-
gle PDZ3 domain (residues 1491–1579) to the 15N-
enriched PDZ2 domain (residues 1357–1442) and
Fig. 1 Superposition of 2D 1H-15N-HSQC NMR spectra recorded on
the 15N-enriched single PDZ2 domain (12 kDa) recorded at 600 MHz
proton frequency at 298 K and pH 7.4 upon titration with the C-
terminal peptide PRK2. a 2D 1H-15N-HSQC NMR spectra of PDZ2
upon titration with PRK2 at various molar ratios up to 1:30 [Black
(ligand free), red (1:1), green (1:3), blue (1:5), yellow (1:7), magenta
(1:10), cyan (1:20), and red (1:30)]. b Weighted chemical shift
perturbation (CSP) of residue T30 from PDZ2 as a function of PRK2
peptide concentration. Curve fitting was carried out in ORIGIN
(www.originlab.com). c 2D 1H-15N-HSQC NMR spectra of PDZ3 upon
titration with PRK2 at various molar ratios up to 1:10 recorded at
700 MHz proton frequency at 298 K and pH 7.4 [Black (ligand free),
red (1:2), green (1:4), blue (1:6), magenta (1:8), and cyan (1:10)]
Dicks et al. BMC Molecular and Cell Biology           (2019) 20:23 Page 3 of 12
monitored their interaction by recording a series of
2D 1H-15N-HSQC NMR spectra (Fig. 4a). Only very
minor, if at all, chemical shift differences could be ob-
served (Fig. 4b). However, the final maximal stoichi-
ometry of PDZ2 and PDZ3 was approx. 1:1 due to
solubility issues.
Furthermore, we analyzed the NMR chemical shift dif-
ferences between the isolated PDZ2 domain and PDZ2
as part of the PDZ2/3 tandem domain in absence as well
in the presence of the APC peptide at a molar ratio of 1:
30 [25–27]. This study clearly demonstrates that the
structure of the apo-PDZ2 domain does not differ from
Fig. 2 a Superposition of a representative region of the 2D 1H-15N-HSQC NMR spectra of PDZ2 in the absence (red) and presence of PDZ3 (blue).
b Only very minor chemical shift differences could be observed, if at all. The final maximal stoichiometry of PDZ2 and PDZ3 was approximately 1:1
Fig. 3 Superposition of selected regions of 2D 1H-15N-HSQC NMR spectra of PDZ2, PDZ3, and PDZ2/3. The selected regions highlight congruent
NMR resonances of the apo-single domains PDZ2 (red) and PDZ3 (green) as well as the PDZ2/3 tandem domain (black)
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the structure of PDZ2 as part of the PDZ2/3 tandem do-
main, because chemical shift differences in the 2D
1H-15N-HSQC NMR spectra could not be detected (Figs.
1, 3, and 4). Obviously, a significant interaction between
the PDZ domains 2 and 3 does not exist in the apo-form
of the PDZ2/3 tandem domain [25]. In contrast to this,
however, the protein-peptide complex of the single
PDZ2 domain and the PDZ2 domain as part of the tan-
dem domain PDZ2/3 complexed with APC peptide show
NMR chemical shift differences in the respective 2D
1H-15N-HSQC spectra (Fig. 4). Major NMR chemical
shift perturbations were observed on the back of the
PDZ2 domain, i.e. opposite to the canonical PDZ bind-
ing cleft, mainly for EF (H94, L95, L97) and for EA
(L19), while other signals do not show any chemical shift
differences in the 2D 1H-15N-HSQC NMR spectra (T31)
(Fig. 4 a, b). NMR resonances amide backbone reso-
nances of PDZ3 are also altered, albeit to a slightly lesser
extent (Fig. 4c, d and Fig. 5). In comparison to the apo-
form of the PDZ2/3 tandem domain, the NMR line
widths only slightly increase for the APC-bound form of
the PDZ2/3 tandem domain (Fig. 4). This suggests an
equilibrium between free and interacting PDZ domains
within the PDZ2/3 tandem. Noteworthy, these NMR
Fig. 4 After the titration of the PDZ2 and PDZ2/3 tandem domains with the APC peptide, repectively, NMR amide backbone resonances of PDZ2 differ in
their frequencies (a, b). Resonances of residues located at the back of PDZ2 domain at β-strand EA (Leu-19) and β-strand EF (His-94, Leu-95, Leu-97) are
not congruent anymore. Other resonances of the PDZ2 domain, like T31, remain unaltered. NMR resonances amide backbone resonances of PDZ3 are also
altered, albeit to a slightly lesser extent (c, d)
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spectra clearly show that both PDZ domains of PDZ2/3
tandem are folded both in the free and APC-bound form
(Figs. 3 and 4). Finally, the free and APC-bound NMR
spectra of the individual PDZ2 domain also exclude an
APC-induced dimerisation of PDZ2 (Figs. 3 and 4).
HADDOCK-based molecular docking calculations
A total of 10 clusters were computed, of which the best
one with an overall HADDOCK software score of −92.7 ±
13.9 containing 8 individual structures was selected for
further analysis (Fig. 6). The HADDOCK statistics for the
APC-bound PDZ2/3 tandem domain from PTPN13 are
listed in Table 2. Based on the NMR chemical shift per-
turbation analysis, a fully consistent molecular
HADDOCK-generated model of the PDZ2/3 complex in
the APC-bound state that fulfills the experimental chem-
ical shift perturbation restraints could be calculated, in
which β-strands 1 (βA) and 6 (βF) are part of the PDZ2/3
tandem domain interface (Fig. 6). The best HADDOCK
cluster contains 8 structural models of the APC-bound
PDZ2/3 tandem domain from PTPN13 that exhibit low
van der Waals, electrostatic, desolvation, and restraint vio-
lation energies (Table 2). Noteworthy, a certain degree of
rotational freedom for the two PDZ domains can be ob-
served reflected in an RMSD value from the overall
lowest-energy structure of 9.7 ± 0.7 (Table 2, Fig. 6b).
Nonetheless, the canonical PDZ binding clefts are always
facing the solvent (Fig. 6b). Thus, the PDZ2-PDZ3 inter-
face is located on the opposite site with a buried surface
area of 1215.5 ± 206.2 Å2 (Table 2).
Discussion
Several previous studies have shown that various pro-
teins, such as PTPN13, contain multiple PDZ domainsd
that these PDZ domains are clustered [1, 2]. The struc-
tures of different PDZ tandems have already been char-
acterized to a great extent. These studies have revealed
that the function of consecutive PDZ domains particu-
larly depends on the relative orientation of the domains
to one other [2, 23, 29]. For instance, the domains 4 and
5 of the GRIP protein have a short linker and a fixed do-
main orientation. While the binding pocket of PDZ4 is
closed and the domain is not involved in the peptide
interaction, the PDZ domain itself and the linker be-
tween these domains are crucial for the binding of a re-
ceptor tail to PDZ5 [22]. On the contrary, the PDZ
domains 1 and 2 of PTPN13 both interact with different
peptides. Previously, a binding study revealed that an
allosteric effect, triggered by a domain-domain interface
between PDZ1 and PDZ2, modulates the binding prop-
erties of the PDZ2 domain [21].
In this study, we have observed different binding char-
acteristics of an APC-derived peptide ligand for the iso-
lated PDZ2 domain in comparison to the PDZ2 domain
when being part of a PTPN13 PDZ2/3 tandem con-
struct. The reason for the different dissociation con-
stants for PDZ2, listed in Table 1, is either the presence
or, respectively, the absence of the PDZ3 domain. This is
in concordance with previously described allosteric
effects caused by domain-domain interaction between
the PDZ domains 1 and 2 of PTPN13 [5, 21, 30]. To-
gether with these previous results, our data now allow
for the first time to generate of an overall model for the
PTPN13 domain triplet PDZ1–3, that reveals the crucial
role of the PDZ2 domain. The analysis of the NMR
chemical shift differences between spectra of the single
PDZ2-APC complex and PDZ2 as a part of the PDZ2/3-
APC complex (together with the results obtained from
the titration of the single PDZ3 domain with the single
PDZ2 domain) suggest an interaction between the two
PDZ domains 2 and 3 when PTPN13 is complexed with
APC, in sharp contrast to the peptide ligand-free PDZ2/
3 tandem domain of PTPN13. The numerous NMR
chemical shift perturbations observed for EA and EF of
PDZ2 are among the most prominent and are probably
caused by the presence of the PDZ3 domain and maybe
even the linker region between these two adjacent PDZ
Table 1 Dissociation constants (KD) of APC and PRK2 for the
single PDZ2 and PDZ3 [12] domains as well as for the PDZ2/3
tandem domain of PTPN13
Domain KRHSGSYLVTSV (APC)
KD [μM]
PDZ2 286 ± 21
PDZ3 721 ± 148
PDZ2 in PDZ2/3 211 ± 70
PDZ3 in PDZ2/3 2574 ± 770
Domain MFRDFDYIADWC (PRK2)
KD [μM]
PDZ2 661 ± 71
PDZ3 318 ± 47
Table 2 HADDOCK [28] statistics of the best cluster containing
8 structures (cluster size) of the APC-bound PDZ2/3 tandem
domain from PTPN13. RMSD is the root mean square deviation
of atomic positions from the overall lowest-energy structure
PTPN13 PDZ2/3 tandem domain-APC complex
HADDOCK-Score: −92.7 ± 13.9
Cluster Size: 8
RMSD [Å]: 9.7 ± 0.7
Van-der-Waals Energy [kcal/mol− 1]: 19.2 ± 13.0
Electrostatic Energy [kcal/mol−1]: −463.8 ± 59.7
Desolvation Energy [kcal/mol− 1]: 14.5 ± 4.9
Restraint violation Energy [kcal/mol− 1]: 48.4 ± 42.8
Buried Surface Area [Å2]: 1215.5 ± 206.2
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domains. These NMR chemical shift differences are indi-
cative of a long-range allosteric effect, which is most
likely caused by PDZ3 interacting with the backside of
the PDZ2 domain within the APC peptide-bound PDZ2/
3 tandem domain of PTPN13. These results clearly indi-
cate that, upon titration with the APC peptide, the
PDZ2 and PDZ3 domain interact with each other and
the equilibrium (partly) shifts towards the PDZ2/PDZ3
complex state (Fig. 5). The HADDOCK-generated model
of PDZ2/3 complex in the APC-bound state with an
overall docking software score of −92.7 ± 13.9 is consist-
ent with experimental chemical shift perturbation re-
straints and reveals that both canonical PDZ binding
clefts are facing the solvent (Fig. 6 b, Table 2). The
PDZ2/3 tandem domain interface, which contains PDZ
β-strands 1 (βA) and 6 (βF) is located on the opposite
site to create a buried surface area of 1215.5 ± 206.2 Å2
(Table 2). Despite a residual rotational freedom of the
two PDZ domains within in the cluster of 8 structural
models of the APC-bound PDZ2/3 tandem domain from
PTPN13, the canonical PDZ binding clefts are always
orientated towards the solvent (Fig. 6b). Presumably, this
residual degree of rotational heterogeneity of the PDZ
domains is due to the limited number of chemical shift
perturbations restraints. Nonetheless, the canonical pep-
tide binding clefts of PDZ2 and PDZ3 are distant from
the PDZ2/3 tandem domain interface allowing for allo-
steric regulation of PTPN13 (Fig. 6b).
Furthermore, we could also observe NMR chemical
shift perturbations for amino acids located in the core of
the domain of PDZ2, ranging from the distal regions of
the domain to the ligand-binding site in concordance
with previous studies [3–5]. Based on this intra-domain
allosteric modulation, the interaction with PDZ3 pre-
sumably causes crucial structural changes in the ligand
binding site of PDZ2 that are located opposite to the do-
main interface (Figs. 5 and 6b). The NMR chemical shift
perturbations are observed for the entire binding loop
that consists of the binding motive, β-strand EB and α-
helix DB. In conclusion, the interaction between PDZ2
and PDZ3 might induce a structural change from the
interface to the binding loop of PDZ2, thereby affecting
its peptide binding characteristics (Table 1). The result
of this allosteric effect can be directly observed by
changes of the APC dissociation constants KD for PDZ2.
This indicates that interaction between the PDZ-PDZ
domains can indeed modify PDZ ligand binding charac-
teristics (Table 1).
Even though the binding behaviour of PDZ domains
has been intensively studied, the functional conse-
quences are still not completely understood. Previous
studies show [30] that the properties of PDZ domains
must be interpreted as a whole to establish a functional
model of multi-PDZ domain complexes as found in
PTPN13 [21]. The biochemical and structural data on
PTPN13 presented in this work clearly demonstrate two
facts: firstly, PRK2 also interacts with PDZ2 thereby ex-
tending the number of known interaction partners of
PDZ2 from PTPN13 [1, 8, 9]. Secondly, PDZ2 is alloste-
rically modulated by PDZ3. The titration of PDZ2 with
the APC-derived peptide reveals NMR chemical shift
perturbations on the entire domain, with major changes
mainly observed for hydrophobic amino acids. The ap-
pearance of NMR chemical shift differences on the en-
tire domain suggests an allosteric network induced by
the binding of the APC-derived peptide. A previous ana-
lysis of allosteric interactions in PDZ2 [3, 5, 30, 31]
showed, that residues within van-der-Waals contact
distance can mediate conformational changes in a PDZ
domain. We propose that peptides with hydrophobic
amino acids at position P0, like valine in the APC pep-
tide, initiate a conformational change by a van der Waals
interaction in the ligand binding site, which is
Fig. 5 Colour-coded backbone hydrogen and nitrogen chemical
shift differences between the single PDZ2-APC complex and PDZ2-
APC when being part of the PDZ2/3-APC complex. The analysis is
based on the structure of the single PDZ2 domain [27]. The α-
helices DA and DB correspond to α1 and α2, and the β-strands EA,
EB, EC, ED, EE, and EF correspond to β1 to β6, respectively.
According to the given scale, the yellow to red colour gradient of
the ribbon structure represents smaller to larger NMR chemical shift
differences. Gray colouring indicates that either no chemical shift
differences were observed or no data were available.
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propagated through a hydrophobic network within the
domain. Therefore, ligands that carry a hydrophobic
amino acid at position P0 might act as an inductor of an
intra-domain structural signalling network mediated by
the hydrophobic core of the PDZ domain [3–5]. This
binding study of the PDZ2/3 tandem domain with the
APC-derived peptide revealed that APC chooses PDZ2
over PDZ3 as a native binding partner (Table 1). It is
remarkable that the binding affinity for the APC peptide
towards PDZ2 in the tandem domain is slightly higher
than for the single PDZ2 domain (KD ~ 211 μM vs KD ~
286 μM) while the binding affinity of the APC peptide for
PDZ3 is even lowered (KD ~ 721 μM vs KD ~ 2574 μM).
The latter KD value indicates that significant binding of
APC to PDZ3 in the tandem domain will most likely not
occur under physiological conditions.
Based on the results from the NMR chemical shift per-
turbation analysis and HADDOCK molecular docking
calculations we conclude, that an allosteric effect modu-
lates the APC-binding characteristics of PDZ2 from
PTPN13 (Fig. 7). Although peptides rather than the
corresponding full-length proteins have been used here,
numerous studies have shown before that the last four
to six carboxy-terminal amino acids are essential for lig-
and binding [32–34] to PDZ domains. A previous study
on the binding characteristics of the PDZ domains 1 and
2 from PTPN13 clearly showed, that the single PDZ2
domain is able to bind to peptide ligands from several
Fig. 6 a For PDZ2 [27], T14, F15, E16, E18, N70, H94, and L95 were selected as AIRs in HADDOCK and are coloured in blue [28]. For a homology
model of PDZ3, E17, V18, K19, L20, S98, and L100 were set as AIRs, also shown in blue. b HADDOCK-based [28] structural model of the PDZ2/3
tandem domain of PTPN13 in the APC-bound state. β-strands are highlighted in yellow, α-helices in red, and regions void of regular secondary
structural elements in green. β-strands 1 (βA) and 6 (βF) of the PDZ2/3 tandem domain interface are indicated
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classes, such as I (APC) and III (RIL) [21]. In the PDZ1/
2 tandem construct, however, PDZ2 binding is appar-
ently limited to class I ligands only [21]. In our study we
could now observe that, in comparison to the isolated
PDZ2 domain, the binding capacity of PDZ2 in the
PDZ2/3 tandem domain is slightly higher for the class I
ligand APC (Table 1). The NMR line widths only slightly
increase for the APC-bound form of the PDZ2/3 tandem
domain (Fig. 4). This suggests an equilibrium between
free and interacting PDZ domains within the PDZ2/3
tandem. Upon APC binding, this equilibrium shifts, pre-
sumably during a process of conformations selection, to-
wards the compact form with a higher affinity of PDZ2
for, in which the state of two PDZ domains of the
PDZ2/3 tandem interacting with each other is more
populated (Figs. 6 and 7).
Our data on the PTPN13 PDZ2/3 tandem domain are
therefore consistent with and complement findings for the
PDZ1/2 tandem, as the binding affinity for the APC pep-
tide ligand is increased in the PDZ 2/3 tandem domain in
comparison to the single PDZ2 domain [21] (Table 1).
Furthermore, since PDZ1 does bind to PDZ2 in the ab-
sence of ligand, PDZ3 apparently has to compete with
PDZ1 in the full-length molecule or at least in the PDZ1/
2/3 domain triplet [21] (Fig. 7). Obviously, PDZ2 is regu-
lated by the adjacent PDZ domains 1 and 3 in the triplet
PDZ123 domain cassette and is thus pivotal as most
known binding partners of PTPN13 interact with the
PDZ2 domain that also includes PRK2 [1]. In the tandem
PDZ2/3 domain of PTPN13, PDZ2 apparently exhibits an
increased affinity for class I ligands, such as APC (Table 1)
. In full-length PTPN13 however, this binding behaviour
might be even further modulated by PDZ1.
This modulation of binding affinities of PTPN13 for its
ligands might also lead to the formation of
supramolecular protein complexes through which
PTPN13 exhibits its well established scaffolding func-
tions in several cellular processes such as cytokinesis
and actin-cytoskeletal rearrangement [1]. This might
also explain as to why the observed in vitro affinities of
PTPN13 for APC and PRK2 are low in comparison to
known examples for PDZ-ligand interactions [1, 35–37].
Interestingly, our finding that the C-terminus of PRK2
can, in principle, bind to two adjacent PDZ domains in
mouse PTPN13 could be of physiological relevance. It
has been demonstrated that PRK2 can form dimers. The
amino-terminus of PRK2 can bind to the kinase domain
of PRK2 in trans leading to an inactive dimer [38]. The
weak binding affinity we observed for binding to the
individual PDZ domains might help to discriminate
between binding to monomeric or dimeric PRK2, as
only the latter would bind with higher affinity given
its potential simultaneous binding to two PDZ do-
mains. Along this line it has been demonstrated that
the PDZ4 domain of PTPN13 binds the RhoGAP pro-
tein PARG1, which in principle could be a negative
regulator of Rho-dependent PRK2 [39]. It is conceiv-
able that the PDZ2–4 domains form a module that
mechanistically contributes to the spatial inactivation
of PRK2. This could be important for example for the
coordinated inactivation of PRK2 in vivo during regu-
lation of cytokinesis, a process PTPN13 and PRK2
have both been implicated in [40, 41].
Conclusions
Taken together, our study suggests that the PDZ2 of
PTPN13 plays a central role in the triplet cassette
PDZ123 and that PDZ2 is regulated by the adjacent PDZ
domains 1 and 3 (Fig. 7). This is in agreement with a
previously published study [21] on PDZ1/2. Based on
NMR chemical shift perturbation experiments and a
molecular HADDOCK model of the PDZ2/3 tandem do-
main from PTPN13, the proximate domains PDZ1 and
PDZ3 interact with a mutually exclusive surface patch
on PDZ2 located opposite to the canonical ligand bind-
ing site of PDZ domains, which mainly consists of the
two β-strands EA and EF (Figs. 5 and 6a, b). In conclu-
sion, an extended model of PDZ1–3 could be established
that stresses the central role of PDZ2 in the PDZ1/2/3
domain triplet within APC-bound PTPN13 (Fig. 7). Des-
pite the linker sequences located between them, the first
three PDZ domains of PTPN13 might hence modulate
their affinity for physiological targets, at least for the
PDZ2/APC interaction.
Methods
Molecular biology
Bacterial expression plasmids pGEX-2 T-PDZ2 (PTPN13
residues 1347–1450), pGEX-2 T-PDZ3 (PTPN13 residues
Fig. 7 Schematic functional model of the APC-bound PDZ1/2/3
domain triplet from PTPN13. Note, the proximate domains PDZ1 and
PDZ3 interact with a mutually exclusive surface patch on PDZ2
located opposite to the canonical ligand binding site of PDZ domains
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1474–1580), and pGEX-2 T-PDZ2/3 (PTPN13 residues
1347–1580) were constructed by sub-cloning of PCR-
generated PTPN13 cDNA fragments in-frame into appro-
priate pGEX-2 T vectors.
Isotopic enrichment of proteins
As previously published, isotope-labeled proteins were
prepared by growing E. coli BL21 (DE3) cells in isotope-
enriched minimal media using 13C glucose and/or 15N
ammonium chloride as carbon and nitrogen sources [25,
42–47].
Expression and purification of PDZ domains from PTPN13
GST-fusion proteins were expressed in E. coli
BL21(DE3) under ampicillin and chloramphenicol selec-
tion. In order to generate 15N isotopically-enriched pro-
teins, cells were grown in minimal media [25]. Proteins
with a natural isotope distribution were produced at
37 °C in Luria broth media [48, 49]. In either case, cells
were grown to an optical density of approx. 0.7 (mea-
sured at 595 nm) and protein expression was induced by
0.75 mM IPTG. Then, the cells were grown for an add-
itional period of 16 h. After increasing the IPTG concen-
tration to 1 mM, the cells were incubated for an
additional period of 2 h. The cells were harvested and re-
suspended in phosphate buffered saline (PBS) at pH 7.4
and EDTA-free protease inhibitors (Roche) were added
before cells were lysed in a micro fluidiser (Microfluidics
Corporation. Cell debris was removed by centrifugation
at 10,200 g and at 4 °C for 45 min. Afterwards, the super-
natant was incubated with Glutathione Sepharose 4B
beads (GE Healthcare) at 20 °C for 60 min. The GST-tag
was subsequently cleaved off through incubation with
Thrombin protease (GE Healthcare) for 12 h at 4 °C.
Then, the protein was eluted from the Glutathione
Sepharose beads with phosphate buffered saline (PBS) at
20 °C. Protein containing fractions were pooled and con-
centrated in a Millipore concentrator with molecular
weight cut-offs of 5000–10,000 Da, frozen in liquid ni-
trogen, and finally stored at − 80 °C until further use.
The integrity of purified proteins was checked by SDS-
PAGE and mass spectrometry (data not shown).
NMR spectroscopy
NMR spectra were acquired at 298 K on Bruker DRX
600 and AVANCE III HD 700 spectrometers. Typically,
NMR samples contained 0.1–0.5 mM uniformly 13C
and/or 15N-enriched protein in PBS buffer at pH 7.4 in-
cluding 10% D2O [42–44]. All data were processed with
either NMRPipe [50] and analyzed with NMR View [51]
or TopSpin (www.bruker.com). The backbone assign-
ments were obtained from the BioMagResBank acces-
sion numbers 15,199 (PDZ2/3) [25] and 5131 (PDZ2)
[25–27, 42, 44, 46]. The interaction between PDZ2 and
PDZ3 was analyzed upon titrating PDZ3 to isotopically
15N-enriched PDZ2 at a molar ratio of 1:1 at 298 K by
recording 2D 1H-15N-HSQC NMR spectra. In this study,
the numbering scheme of the assigned chemical shifts
for PDZ2 (5131) and PDZ23 (15199) has been shifted by
one residue so that, for example, T30 according to the
BMRB entry 5131 now equals T31. Amino-terminally
acetylated dodecapeptides were commercially obtained
from JPT Peptide Technologies (Germany). The peptide
sequences KRHSGSYLVTSV (M = 1332.69 g/mol) and
MFRDFDYIADWC (M = 1580.64 g/mol) correspond to
the last 12 C-terminal residues of APC and PRK2, re-
spectively. APC and PRK2 peptides were titrated with
PDZ2, PDZ3, and PDZ2/3 domains that were isotopic-
ally enriched with 15N. The experiments were carried
out at protein-to-ligand ratios of 1:0, 1:1, 1:3, 1:5, 1:10, 1:
20, and 1:30 at 298 K and pH 7.4. For all binding studies
that included a PDZ3 domain, Dithiothreitol (DTT) was
added to the sample before carrying out the titration in
order to avoid the oxidation of cysteines. The differences
in backbone 1H and 15N NMR chemical shifts were
monitored via 2D 1H-15N-HSQC NMR spectra. The
weighted 1HN and
15N chemical shift differences were
calculated according to the following equation [45, 47]:
Δδobs ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Δδ1HN
 2
þ
Δδ15N
5
 2s
Averaged dissociation constants for the different com-
plexes were calculated from least-squares fitting of the
NMR chemical shift perturbations observed for several
amino acids as a function of ligand concentration. NMR
chemical shift perturbation data were analysed with the
ORIGIN software package (www.originlab.com) as previ-
ously published [12, 52]. The error for KD values was
calculated from the individual fit of several significant
chemical shift perturbations found for the amide reso-
nances located in and/or next to the canonical PDZ
binding cleft. For the PDZ2/APC titration amide reso-
nances of G23, K50, A52, L73, Q80, and A81 of were
used, for the PDZ2/PRK2 titration amide resonances of
T21, G23, T30, Y43, G51, A52, S55, and D56 were used,
for the ‘PDZ2 in PDZ2/3’/APC titration amide reso-
nances of L19, D57, and Q81 were used, and, finally, for
the ‘PDZ3 in PDZ2/3’/APC amide resonances of G159,
F162, S163, K184, L223, and G225 were used.
Molecular dynamics docking
The High Ambiguity Driven protein-protein DOCKing
(HADDOCK) software package was used to generate a
model of the APC-bound PDZ2/3 tandem from PTN13
based on the differential NMR chemical shift perturba-
tions outside the canonical binding cleft of PDZ domains
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between PDZ2/APC and ‘PDZ2 in PDZ2/3’/APC titra-
tion [28]. For PDZ2 [27], T14, F15, E16, E18, N70, H94,
and L95 were selected as active ambiguous interaction
restraints (AIRs). These surface-exposed residues are lo-
cated opposite to the canonical PDZ binding cleft. T14,
F15, E16, and E18 are located on β-strand EA and H94,
L95 on β-strand EF. For a homology model of PDZ3,
E17, V18, K19, L20, S98, and L100 were set as active
AIRs. These residues are also positioned on β-strand EA
(E17, V18, K19, and L20) and β-strand EF (S98 and
L100). Passive AIRs were automatically defined by HAD-
DOCK [28]. The molecular dynamics-based docking is
driven by the experimental restraints, i. e. nmr chemical
shift perturbations extracted from the PTPN13/APC ti-
trations experiments in this case [28]. In HADDOCK,
the entire CHARMM force fields-based docking proced-
ure includes rigid-body energy minimization and semi-
flexible refinement using torsion angle molecular dy-
namics, followed by refinement in explicit water [28].
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